Trials / Unknown
UnknownNCT03751293
A Study of BCMA-directed CAR-T Cells Treatment in Subjects With r/r Multiple Myeloma
A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Hebei Yanda Ludaopei Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, non-randomized study to evaluate the safety and efficacy of C-CAR088 in relapsed or refractory multiple myeloma patient.
Detailed description
The study will include the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation, Lymphodepleting Chemotherapy), C-CAR088 infusion and Follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | C-CAR088 | Autologous BCMA-directed CAR-T cells, single infusion intravenously at a target dose of 1.0-9.0 x 10\^6 anti-BCMA CAR+ T cells/kg |
Timeline
- Start date
- 2019-01-08
- Primary completion
- 2019-10-30
- Completion
- 2020-10-30
- First posted
- 2018-11-23
- Last updated
- 2019-05-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03751293. Inclusion in this directory is not an endorsement.